European journal of nuclear medicine and molecular imaging
-
Eur. J. Nucl. Med. Mol. Imaging · Jun 2006
Controlled Clinical TrialAccuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT.
The purpose of this study was to determine the accuracy of detection of small pulmonary nodules on quiet breathing attenuation correction CT (CTAC) and FDG-PET when performing integrated PET/CT, as compared with a diagnostic inspiratory CT scan acquired in the same imaging session. ⋯ The detection of small pulmonary nodules by breathing CTAC and FDG-PET is relatively poor. Therefore an additional diagnostic thoracic CT scan obtained during suspended inspiration is recommended for thorough evaluation of those patients in whom detection of pulmonary metastases is necessary for management.
-
Eur. J. Nucl. Med. Mol. Imaging · May 2006
Comparative Study Controlled Clinical TrialComparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.
Somatostatin receptor scintigraphy with (111)In-DOTA-D: Phe(1)-Tyr(3)-octreotide ((111)In-DOTA-TOC) and (111)In-DOTA-lanreotide ((111)In-DOTA-LAN) has been used for staging of neuroendocrine tumours (NETs). However, the comparative diagnostic value of these radioligands on a lesion basis has not yet been established. The aim of this study was to compare the diagnostic capacity of (111)In-DOTA-TOC and (111)In-DOTA-LAN scintigraphy in patients with NETs, evaluating whether significant differences exist in lesion imaging with these radioligands. Furthermore, dosimetric data were compared. ⋯ Both (111)In-DOTA-TOC and (111)In-DOTA-LAN are suitable for imaging tumour lesions in patients with NETs and can detect lesions that may not be seen by conventional imaging and (18)F-FDG-PET. Compared with (111)In-DOTA-LAN, (111)In-DOTA-TOC has a superior diagnostic capacity for liver metastases, but a lower diagnostic capacity for metastatic lesions in mediastinum and bone.
-
Eur. J. Nucl. Med. Mol. Imaging · May 2006
Controlled Clinical TrialRole of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
Multiple myeloma (MM) is a malignant B cell and plasma cell disorder which involves the skeleton in more than 80% of patients at diagnosis. The aim of this study was to compare whole-body X-ray (WBXR), MRI and (18)F-FDG PET/CT in patients with MM. ⋯ (18)F-FDG PET/CT appears to be more sensitive than WBXR for the detection of small lytic bone lesions, whereas it has the same sensitivity as MRI in detecting bone disease of the spine and pelvis. On the other hand, MRI may be superior to (18)F-FDG PET/CT in diagnosing an infiltrative pattern in the spine. Therefore, careful evaluation of MM bone disease at diagnosis should include both MRI of the spine and (18)F-FDG PET/CT.
-
Eur. J. Nucl. Med. Mol. Imaging · May 2006
99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody.
The first aim of the study was to determine whether (99m)Tc-HYNIC-annexin V, a marker of cellular stress and apoptosis, can detect ischemic injury in patients with acute stroke. Secondly, we wished to test radiolabeled annexin's ability to monitor therapy in a rodent model of focal ischemic injury. ⋯ Annexin imaging shows foci of increased uptake at sites of ischemic injury in patients with acute stroke. Annexin imaging can assess the effects of therapy for ischemic cerebral injury in rats, suggesting its potential as a non-invasive indicator of drug efficacy in future clinical trials.
-
Eur. J. Nucl. Med. Mol. Imaging · Apr 2006
Comparative StudyCross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom.
SPECT examinations of neurotransmitter systems in the brain have to be comparable between centres to generate a comprehensive data pool, e.g. for multicentre studies. Equipment-specific effects on quantitative evaluations and corresponding methods for compensation, however, have been insufficiently examined. Previous studies have shown that quantitative results may vary significantly according to the imaging equipment used, thereby affecting clinical interpretation of the data. The aim of this study was to determine correction factors for common camera/collimator combinations based on standardised measurements of an anthropomorphic 3D basal ganglia phantom to compensate for the effects of different SPECT camera/collimator equipment. The latter may serve as a model for human studies of the dopaminergic system. ⋯ Measurements of a 3D basal ganglia phantom with various imaging devices revealed linear correlations between measured and true striatal/background ratios. Based on these findings, adjustment of quantitative results between different equipment seems possible, provided that acquisition, reconstruction and evaluation are adequately standardised. The use of identical evaluation methods in phantom and patient studies (comparable shape, size and location of the VOIs) might allow transfer of the calculated correction factors from phantom to studies of the dopaminergic system in patients.